On the stock market since 1996, it operates in the world of health and science. Now — the numbers.
This is an established company with proven profits.
Revenue is spread across several lines; no single product carries the company.
No real growth (4% a year).
The gap is $6.9M. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
Over the last 3 years, sales grew only 3% a year on average. At this size, speeding back up is not easy.
The price action doesn’t yet back an upward turn. Council score: 0/10.
On our five-subject report card, EXAC sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: EXAC is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.